The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
CuATSM Compared With Placebo for Treatment of ALS/MND
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Amyotrophic Lateral Sclerosis 0 0
Condition category
Condition code
Neurological 0 0 0 0
Neurodegenerative diseases
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Study type
Description of intervention(s) / exposure
Treatment: Drugs - Cu(II)ATSM
Treatment: Drugs - Placebos

Active Comparator: Cu(II)ATSM - Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.

Placebo Comparator: Placebo Powder for Oral Suspension - Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.

Treatment: Drugs: Cu(II)ATSM
oral suspension

Treatment: Drugs: Placebos
oral suspension

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Revised ALS Functional Rating Scale (ALSFRS-R) total score (range: 48 [best] to 0 [worst]) - assessment of disease severity
Timepoint [1] 0 0
24 weeks
Primary outcome [2] 0 0
Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS) total score (range: 136 [best] to 0 [worst]) - assessment of cognitive function
Timepoint [2] 0 0
24 weeks
Secondary outcome [1] 0 0
seated slow vital capacity (SVC) - assessment of respiratory function
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
rate of adverse events - tolerability assessment
Timepoint [2] 0 0
24 weeks

Key inclusion criteria
- signed informed consent

- familial or sporadic ALS/MNS by Awaji-shima Consensus Recommendations

- not taking riluzole or on stable dose of riluzole for 4 weeks prior to screening visit

- no prior exposure to agents other than riluzole for treatment of ALS

- adequate bone marrow reserve, renal and liver function

- women of childbearing potential must have a negative pregnancy test and be

- women and men with partners of childbearing potential must take effective
contraception while on treatment
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- presence of a gastrointestinal disorder (eg, malabsorption) that might jeopardize
intestinal absorption of study drug

- inability to perform seated SVC

- known immune compromising illness or treatment

- drug abuse or alcoholism

- clinically significant or active cardiovascular disease

- acute or chronic infection

- diagnosis of malignancy within 2 years prior to screening

- dementia that may affect patient understanding and/or compliance with study
requirements and procedures

- current use of strong inducers or inhibitors of CYPs 2C19 and 2D6

- current us of medications (other than riluzole) that are metabolized predominantly by

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase 2/Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Macquarie University - Macquarie
Recruitment postcode(s) [1] 0 0
- Macquarie

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Collaborative Medicinal Development Pty Limited

Ethics approval
Ethics application status

Brief summary
Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and
efficacy of CuATSM in patients with ALS/MND. Patients will be randomized 1:1 to CuATSM or
placebo for 6 x 28-day cycles (24 weeks) of treatment.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Dominic Rowe, MD
Address 0 0
Macquarie University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Kay Noel, PhD
Address 0 0
Country 0 0
Phone 0 0
(415) 444 9600
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see